• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 74
  • 29
  • 26
  • 9
  • 7
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 165
  • 25
  • 15
  • 14
  • 14
  • 12
  • 12
  • 11
  • 11
  • 10
  • 9
  • 9
  • 9
  • 8
  • 8
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
151

Méthodes non conformes pour des équations aux dérivées partielles avec diffusion

Di Pietro, Daniele Antonio 06 December 2010 (has links) (PDF)
Ce mémoire est un exposé synthétique d'une partie des travaux que j'ai accomplis après la fin de ma thèse. Au cours des dernières années, j'ai été amené à m'intéresser à la discrétisation de problèmes provenant de différentes applications en mécanique des fluides. L'élément commun à tous ces problèmes est la présence de termes diffusifs du second ordre. Pour des raisons différentes, j'ai considéré des discrétisations non conformes, c'est-à-dire, basées sur des espaces discrets non contenus dans l'espace continu naturellement associé à la formulation faible du problème. Plus précisément, dans les travaux présentés dans ce mémoire on retrouve essentiellement deux grandes familles de méthodes : les méthodes dites de Galerkine discontinues et les méthodes volumes finis. Ce document s'organise comme suit. Les Chapitres 1–3 fournissent les renseignements administratifs relatifs au dossier de demande d'habilitation, dont un <EM>curriculum vitæ</EM>, une description succincte de l'ensemble de mes travaux et la liste complète des publications. Les Chapitres 4–5 relatent les efforts entrepris au sujet de la discrétisation de problèmes avec diffusion par des méthodes non conformes. Plus précisément, le Chapitre 4 est consacré aux méthodes de Galerkine discontinues, tandis que le Chapitre 5 traite des méthodes volumes finis. Même si l'accent est généralement mis sur les motivations des travaux et sur le développement de la ligne de pensée, des détails sont fournis quand cela s'avère nécessaire pour apporter un complément d'information par rapport aux publications, ou bien pour indiquer des pistes de recherche futures. Le rapport contient aussi une annexe contenant les résumés des thèses actuellement en cours. Dans la dernière partie de ce mémoire on peut trouver le texte intégral des publications. Pour faciliter la lecture, mes publications sont citées dans le texte avec un numéro progressif, tandis que les articles de la bibliographie générale sont cités avec les initiales des auteurs.
152

Tratamento inovador da compressão medular com reposição enzimática intratecal nas mucopolissacaridoses tipos I e VI : relato de uma série de casos / Innovative treatment of cord compression with trathecal enzyme replacement therapy in mucopolysaccharidoses I and VI: report of a case series

Munõz Rojas, Maria Verônica January 2010 (has links)
As mucopolissacaridoses apresentam uma história natural progressiva, causada por defeitos no metabolismo dos glicosaminoglicanos. Frequentemente graves, as mucopolissacaridoses encurtam de forma considerável a expectativa de vida do paciente. Apesar de que em muitos casos a função intelectual é normal, morbidade neurológica considerável pode ser causada por compressão medular secundária ao acúmulo de glicosaminoglicanos nas meninges. O tratamento deste problema pode requerer a descompressão medular através de laminectomia cervical. A terapia de reposição enzimática endovenosa, para o tratamento de mucopolissacaridose, reduz o acúmulo lisossômico e alivia muitos dos sintomas da doença, porém não oferece benefício direto para o sistema nervoso central uma vez que não atravessa a barreira hemato-encefálica. Esta limitação da reposição enzimática endovenosa levou alguns pesquisadores a trabalhar com uma nova opção de via de liberação medicamentosa de alcance direto no sistema nervoso central, aproveitando o extenso contato que existe entre o líquido cefaloraquidiano e as meninges e com as granulações aracnoideas, para o tratamento de algumas doenças de depósito lisossomal. Estudos em modelos animais têm sido conduzidos e com resultados promissores. Este trabalho se propõe a estudar uma nova via de administração da enzima recombinante, diretamente no espaço liquórico que foi utilizada em dois pacientes com MPS I e em um paciente com MPS VI, com acesso a esta terapêutica através de uso compassivo individual aprovado pelo Comitê de Ética, no Hospital de Clínicas de Porto Alegre. Até então, apenas estudos animais haviam sido realizados abordando esta via de acesso em doenças de depósito lisossomal e estes pacientes foram os primeiros indivíduos com MPS no mundo a receber terapia de reposição intratecal para o tratamento de compressão medular sintomática por depósito de glicosaminoglicanos. Em 2005 um paciente adulto com MPS I apresentando compressão medular foi incluído em um protocolo de terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2006 uma menina com MPS I apresentando compressão cervical medular sintomática também recebeu terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2007 um menino com MPS VI e com compressão medular cervical também foi tratado através de reposição enzimática intratecal por uso compassivo neste mesmo hospital. / The mucopolysaccharidoses present a progressive natural course caused by defects on glycosaminoglycan degradation pathways. Usually severe, the mucopolysaccharidoses considerably shorten patient lifespan. Although in many cases the cognitive function is preserved, considerable neurological morbidity can be present due to spinal cord compression which is secondary to glycosaminoglycan storage in the meninges. Treatment for this complication usually requires surgical intervention with cervical laminectomy for thickened meninges removal. Enzyme replacement therapy used for the treatment of mucopolysaccharidoses reduces lysosomal storage and ameliorates many somatic symptoms but does not provide any direct benefit to central nervous system as the enzyme does not cross the blood-brain-barrier. Due to this limitation of intravenous enzyme replacement therapy some researchers have been working with an alternative option of enzyme delivery with direct action on central nervous system through the extensive close contact provided by cefalo-spinal fluid and meniniges and arachnoid villosities, to the treatment of some lysosomal disorders. Animal model studies have been conducted and some promising results have been achieved. This study intends to present an alternative route for the administration of a recombinant enzyme, directly in the cefalo-spinal fluid, which was used in two patients with mucopolysaccharidosis I and one patient with mucopolysaccharidois VI. These patients gained access to this therapy by individual compassionate use enrollment approved by local Ethics Board at Hospital de Clínicas de Porto Alegre. So far, only animal model trials had been conducted with the use of this administration route in lysosomal storage diseases, and these were the first three patients with mucopolysaccharidoses and cord compression to receive intrathecal enzyme replacement therapy in the world. In 2005, an adult mucopolysaccharidosis I patient presenting cervical cord compression was enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2006, a girl with mucopolysaccharidosis I presenting spinal cord compression was also enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2007, a boy with mucopolysaccharidosis VI and cord compression was enrolled in compassionate use trial of intrathecal enzyme replacement therapy in the same hospital.
153

Experiences of the mobile injection team for multi drug resistant-tuberculosis patients in Ugu District, KwaZulu-Natal

Arjun, Sitha Devi 21 July 2016 (has links)
The purpose of the study was to investigate and describe the experiences of a mobile injection team for multi drug resistant-tuberculosis outpatients, and to design and recommend a mobile injection team guideline based on the experiences of the team members in Ugu District, KwaZulu-Natal and to indicate the support that the MIT require. Phenomenological research was conducted. Convenient census sampling was used as all the seven members of the Ugu District mobile injection team were included. The inclusion criteria was at least six months’ working experience with MDR-TB patients in a mobile injection team at Ugu District, be an enrolled nurse registered with the South African Nursing Council as an enrolled nurse and must have an annual practicing certificate, or be a TB assistant, be willing to participate in the study and be located at the decentralised and satellite site. Data were collected through individual in-depth interviews with the participants. Data were analysed using Giorgi’s method of data analysis. The research findings revealed four broad themes (the perceptions held by the team, challenges, available support and needs to promote the service) and 73 sub-themes. The findings of the study indicate that the MDR-TB outreach injection teams experience many challenges in the community and need to be supported by their management in order to provide quality care to the patients. This study contributes to the development of guidelines to assist the mobile injection teams to provide quality patient care and effective service delivery. Based on the findings, the recommendation is that an intervention study be performed to compare the utilisation of the mobile MDR-TB injection team after implementing the recommendations made and the guidelines developed in this study / Health Studies / D. Litt. et Phil. (Health Studies)
154

Tratamento inovador da compressão medular com reposição enzimática intratecal nas mucopolissacaridoses tipos I e VI : relato de uma série de casos / Innovative treatment of cord compression with trathecal enzyme replacement therapy in mucopolysaccharidoses I and VI: report of a case series

Munõz Rojas, Maria Verônica January 2010 (has links)
As mucopolissacaridoses apresentam uma história natural progressiva, causada por defeitos no metabolismo dos glicosaminoglicanos. Frequentemente graves, as mucopolissacaridoses encurtam de forma considerável a expectativa de vida do paciente. Apesar de que em muitos casos a função intelectual é normal, morbidade neurológica considerável pode ser causada por compressão medular secundária ao acúmulo de glicosaminoglicanos nas meninges. O tratamento deste problema pode requerer a descompressão medular através de laminectomia cervical. A terapia de reposição enzimática endovenosa, para o tratamento de mucopolissacaridose, reduz o acúmulo lisossômico e alivia muitos dos sintomas da doença, porém não oferece benefício direto para o sistema nervoso central uma vez que não atravessa a barreira hemato-encefálica. Esta limitação da reposição enzimática endovenosa levou alguns pesquisadores a trabalhar com uma nova opção de via de liberação medicamentosa de alcance direto no sistema nervoso central, aproveitando o extenso contato que existe entre o líquido cefaloraquidiano e as meninges e com as granulações aracnoideas, para o tratamento de algumas doenças de depósito lisossomal. Estudos em modelos animais têm sido conduzidos e com resultados promissores. Este trabalho se propõe a estudar uma nova via de administração da enzima recombinante, diretamente no espaço liquórico que foi utilizada em dois pacientes com MPS I e em um paciente com MPS VI, com acesso a esta terapêutica através de uso compassivo individual aprovado pelo Comitê de Ética, no Hospital de Clínicas de Porto Alegre. Até então, apenas estudos animais haviam sido realizados abordando esta via de acesso em doenças de depósito lisossomal e estes pacientes foram os primeiros indivíduos com MPS no mundo a receber terapia de reposição intratecal para o tratamento de compressão medular sintomática por depósito de glicosaminoglicanos. Em 2005 um paciente adulto com MPS I apresentando compressão medular foi incluído em um protocolo de terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2006 uma menina com MPS I apresentando compressão cervical medular sintomática também recebeu terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2007 um menino com MPS VI e com compressão medular cervical também foi tratado através de reposição enzimática intratecal por uso compassivo neste mesmo hospital. / The mucopolysaccharidoses present a progressive natural course caused by defects on glycosaminoglycan degradation pathways. Usually severe, the mucopolysaccharidoses considerably shorten patient lifespan. Although in many cases the cognitive function is preserved, considerable neurological morbidity can be present due to spinal cord compression which is secondary to glycosaminoglycan storage in the meninges. Treatment for this complication usually requires surgical intervention with cervical laminectomy for thickened meninges removal. Enzyme replacement therapy used for the treatment of mucopolysaccharidoses reduces lysosomal storage and ameliorates many somatic symptoms but does not provide any direct benefit to central nervous system as the enzyme does not cross the blood-brain-barrier. Due to this limitation of intravenous enzyme replacement therapy some researchers have been working with an alternative option of enzyme delivery with direct action on central nervous system through the extensive close contact provided by cefalo-spinal fluid and meniniges and arachnoid villosities, to the treatment of some lysosomal disorders. Animal model studies have been conducted and some promising results have been achieved. This study intends to present an alternative route for the administration of a recombinant enzyme, directly in the cefalo-spinal fluid, which was used in two patients with mucopolysaccharidosis I and one patient with mucopolysaccharidois VI. These patients gained access to this therapy by individual compassionate use enrollment approved by local Ethics Board at Hospital de Clínicas de Porto Alegre. So far, only animal model trials had been conducted with the use of this administration route in lysosomal storage diseases, and these were the first three patients with mucopolysaccharidoses and cord compression to receive intrathecal enzyme replacement therapy in the world. In 2005, an adult mucopolysaccharidosis I patient presenting cervical cord compression was enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2006, a girl with mucopolysaccharidosis I presenting spinal cord compression was also enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2007, a boy with mucopolysaccharidosis VI and cord compression was enrolled in compassionate use trial of intrathecal enzyme replacement therapy in the same hospital.
155

Tratamento inovador da compressão medular com reposição enzimática intratecal nas mucopolissacaridoses tipos I e VI : relato de uma série de casos / Innovative treatment of cord compression with trathecal enzyme replacement therapy in mucopolysaccharidoses I and VI: report of a case series

Munõz Rojas, Maria Verônica January 2010 (has links)
As mucopolissacaridoses apresentam uma história natural progressiva, causada por defeitos no metabolismo dos glicosaminoglicanos. Frequentemente graves, as mucopolissacaridoses encurtam de forma considerável a expectativa de vida do paciente. Apesar de que em muitos casos a função intelectual é normal, morbidade neurológica considerável pode ser causada por compressão medular secundária ao acúmulo de glicosaminoglicanos nas meninges. O tratamento deste problema pode requerer a descompressão medular através de laminectomia cervical. A terapia de reposição enzimática endovenosa, para o tratamento de mucopolissacaridose, reduz o acúmulo lisossômico e alivia muitos dos sintomas da doença, porém não oferece benefício direto para o sistema nervoso central uma vez que não atravessa a barreira hemato-encefálica. Esta limitação da reposição enzimática endovenosa levou alguns pesquisadores a trabalhar com uma nova opção de via de liberação medicamentosa de alcance direto no sistema nervoso central, aproveitando o extenso contato que existe entre o líquido cefaloraquidiano e as meninges e com as granulações aracnoideas, para o tratamento de algumas doenças de depósito lisossomal. Estudos em modelos animais têm sido conduzidos e com resultados promissores. Este trabalho se propõe a estudar uma nova via de administração da enzima recombinante, diretamente no espaço liquórico que foi utilizada em dois pacientes com MPS I e em um paciente com MPS VI, com acesso a esta terapêutica através de uso compassivo individual aprovado pelo Comitê de Ética, no Hospital de Clínicas de Porto Alegre. Até então, apenas estudos animais haviam sido realizados abordando esta via de acesso em doenças de depósito lisossomal e estes pacientes foram os primeiros indivíduos com MPS no mundo a receber terapia de reposição intratecal para o tratamento de compressão medular sintomática por depósito de glicosaminoglicanos. Em 2005 um paciente adulto com MPS I apresentando compressão medular foi incluído em um protocolo de terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2006 uma menina com MPS I apresentando compressão cervical medular sintomática também recebeu terapia de reposição enzimática intratecal por uso compassivo no Hospital de Clínicas de Porto Alegre. Em 2007 um menino com MPS VI e com compressão medular cervical também foi tratado através de reposição enzimática intratecal por uso compassivo neste mesmo hospital. / The mucopolysaccharidoses present a progressive natural course caused by defects on glycosaminoglycan degradation pathways. Usually severe, the mucopolysaccharidoses considerably shorten patient lifespan. Although in many cases the cognitive function is preserved, considerable neurological morbidity can be present due to spinal cord compression which is secondary to glycosaminoglycan storage in the meninges. Treatment for this complication usually requires surgical intervention with cervical laminectomy for thickened meninges removal. Enzyme replacement therapy used for the treatment of mucopolysaccharidoses reduces lysosomal storage and ameliorates many somatic symptoms but does not provide any direct benefit to central nervous system as the enzyme does not cross the blood-brain-barrier. Due to this limitation of intravenous enzyme replacement therapy some researchers have been working with an alternative option of enzyme delivery with direct action on central nervous system through the extensive close contact provided by cefalo-spinal fluid and meniniges and arachnoid villosities, to the treatment of some lysosomal disorders. Animal model studies have been conducted and some promising results have been achieved. This study intends to present an alternative route for the administration of a recombinant enzyme, directly in the cefalo-spinal fluid, which was used in two patients with mucopolysaccharidosis I and one patient with mucopolysaccharidois VI. These patients gained access to this therapy by individual compassionate use enrollment approved by local Ethics Board at Hospital de Clínicas de Porto Alegre. So far, only animal model trials had been conducted with the use of this administration route in lysosomal storage diseases, and these were the first three patients with mucopolysaccharidoses and cord compression to receive intrathecal enzyme replacement therapy in the world. In 2005, an adult mucopolysaccharidosis I patient presenting cervical cord compression was enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2006, a girl with mucopolysaccharidosis I presenting spinal cord compression was also enrolled in a compassionate use trial of intrathecal enzyme replacement therapy, at the Hospital de Clínicas de Porto Alegre. In 2007, a boy with mucopolysaccharidosis VI and cord compression was enrolled in compassionate use trial of intrathecal enzyme replacement therapy in the same hospital.
156

Efeito da hepatectomia parcial associada à administração de fatores nutricionais hepatotróficos sobre a morfologia, função e expressão de genes pró-fibróticos na cirrose hepática em ratos Wistar induzida por tiocetamida / Effects of partial hepatectomy associated with administration of nutritional hepatotrophic factors in morphology, function and expression of pro-fibrotic genes in thioacetamide-induced liver cirrhosis in Wistar rats

Mauricio de Rosa Trotta 15 December 2011 (has links)
O presente trabalho avaliou o papel da solução parenteral de fatores hepatotróficos nutricionais em animais com cirrose submetidos à hepatectomia parcial. Este procedimento é temido nestes animais devido à possibilidade de ocorrência de falência hepática aguda, já que a remoção de um fragmento do fígado reduz ainda mais a capacidade funcional de um órgão já comprometido. Além disso, é conhecido que o fígado cirrótico diminui sua capacidade regenerativa, fato que atrasa a recuperação do animal, bem como também regenera cirroticamente. Esses fatores, aliados, contribuem para uma considerável taxa de mortalidade pós-operatória. Porém, há algumas situações em que estes pacientes precisam ser submetidos a ressecções hepáticas, tais como traumas, infecções e neoplasias. De fato, a presença de hepatocarcinomas representa a maior indicação deste procedimento em fígados cirróticos. Por outro lado, tem-se mostrado que a administração parenteral de solução de fatores hepatotróficos nutricionais (FHN), uma mistura de aminoácidos, vitaminas, sais minerais e hormônios, aumenta consideravelmente a proliferação celular e o tamanho do fígado em animais sadios, com fibrose e com cirrose. Nestes dois últimos, além do crescimento hepático, ocorre também uma importante redução na quantidade de colágeno, significando uma melhora morfológica que, por muitas vezes, resulta em uma melhora funcional. Sendo assim, o objetivo do presente trabalho foi o verificar se o uso de fatores hepatotróficos nutricionais traria também uma melhora morfológica e funcional em animais com cirrose induzida por tiocetamida após uma ressecção hepática de 40%. Utilizou-se 40 ratos (Rattus norvegicus) Wistar fêmeas cuja indução da cirrose foi pela administração intraperitoneal de tiocetamida. Ao final deste período, e após 10 dias de descanso, todos os animais foram submetidos a uma hepatectomia parcial (HP) de 40%. Foram então divididos em dois grupos: um que recebeu intraperitonealmente a solução de fatores hepatotróficos nutricionais durante 12 dias, designado grupo HP+FHN, e outro que recebeu solução fisiológica nas mesmas condições, formando o grupo HP+S. Os seguintes parâmetros foram avaliados no término do período experimental: dados biométricos (peso do fígado, IHS: índice hepassomático e IHC: índice hepatocarcaça), bioquímica hepática plasmática (AST, ALT, fosfatase alcalina, bilirrubina total e albumina), quantificação da densidade volumétrica de colágeno hepático por morfometria, quantificação do índice de proliferação celular por imunohistoquímica para PCNA e expressão de genes pró-fibróticos (MMP2, TIMP1, Cola1 e TGFb1) por PCR em tempo real. De fato, os fígados dos animais do grupo HP+FHN estavam maiores do que os animais do grupo HP+S (aumentos de 8,4%, 5,6% e 8,4% no peso do fígado, IHS e IHC respectivamente), e também apresentaram maior índice de proliferação de hepatócitos (44,9%). Ocorreu também redução de 27,9% na densidade volumétrica do colágeno hepático no grupo que recebeu FHN comparandose com o grupo que recebeu solução salina. Esta redução também foi observada na expressão do gene de colágeno a1, que foi de 53%. Porém, não houve diferença nos demais genes avaliados. Dentre os parâmetros bioquímicos, apenas a fosfatase alcalina mostrou redução. Os resultados obtidos permitem concluir que o uso de FHN acarreta em um aumento da regeneração hepática acompanhado de uma redução da quantidade de colágeno e, esses achados, em conjunto, podem representar uma condição benéfica na recuperação de pacientes com cirrose submetidos à ressecção hepática / The current study evaluated the role of parenteral solution of nutritional hepatotrophic factors in animals with cirrhosis undergoing partial hepatectomy. This procedure is fearful in these animals due to the possibility of acute liver failure, since removal of a liver fragment further reduces the functional capacity of an already compromised organ. Moreover, it is known that cirrhotic liver decreases its regenerative capacity, which impairs the recovery of the animal, and also regenerates cirrhotic. These factors, together, contribute to a considerable rate of postoperative mortality. However, there are some situations when these patients need to be submitted to liver resection, such as trauma, infections and neoplasm. In fact, the presence of hepatocellular carcinoma represents the most important indication of this procedure in patients with cirrhosis. On the other hand, it has been shown that parenteral administration of a solution of the nutritional hepatotrophic factors (NHF), a mixture of amino acids, vitamins, minerals and hormones, significantly increases cell proliferation and liver size in healthy, fibrotic and cirrhotic animals. In the two latter, beyond the liver growth, there is also a significant reduction in the amount of collagen, meaning a morphological enhancement, resulting in a functional improvement. Therefore, the objective of this study was to determine whether the use of nutritional hepatotrophic factors would also lead a morphological and functional improvement in animals with thioacetamide-induced cirrhosis after 40% liver resection. We used 40 rats (Rattus norvegicus) female Wistar whose cirrhosis was induced by intraperitoneal administration thioacetamide. At the end of this period, and after 10 days of rest, all animals were underwent a partial hepatectomy (PH) of 40%. They were then divided into two groups: one that received intraperitoneally a solution of nutritional hepatotrophic factors for 12 days, designated PH+NHF group, and another that received saline under the same conditions, forming the PH+S group. The following parameters were evaluated at the end of the trial period: biometrics (liver weight, HSI hepatossomatic index, and HCI hepatocarcass index), plasmatic liver biochemistry (AST, ALT, alkaline phosphatase, total bilirubin and albumin), quantification of volume density of collagen in liver morphology, quantification of cell proliferation by immunohistochemistry for PCNA and expression of pro-fibrotic genes (MMP2, TIMP1, TGF1 and Cola1) by real-time PCR. In fact, the livers of animals in group PH+NHF were larger than the animals in PH+S group (increases of 8.4%, 5.6% and 8.4% in liver weight, HSI and HCI, respectively), and also had higher rates of proliferation of hepatocytes (44.9%). There was also a 27.9% reduction in liver volume density of collagen in the group receiving NHF compared with the group that received saline. This reduction was also observed in gene expression of collagen a1, which was 53%. However, there were no differences in other genes evaluated. Among biochemical parameters, only the alkaline phosphatase showed a reduction. The results indicate that the use of NHF leads to an increase in liver regeneration accompanied by a reduction in the amount of collagen, and these findings, together, can represent a beneficial condition in the recovery of patients with cirrhosis undergoing liver resection
157

Etude d'injections de Sobolev critiques dans les espaces d'Orlicz et applications / Study of the critical embedding ofthe lack of Sobolev into the Orlicz spaces and applications

Ben Ayed, Inès 28 December 2015 (has links)
Dans cette thèse, on s'est attaché d'une part à d'écrire le défaut de compacité de l'injection de Sobolev critique dans les différentes classes d'espaces d'Orlicz, et d'autre part à étudier l'équation de Klein-Gordon avec une non-linéarité exponentielle. Ce travail se divise en trois parties. L'objectif de la première partie est de caractériser le défaut de compacité de l'injection de Sobolev de $H^2_{rad}(R^4)$ dans l'espace d'Orlicz $mathcal{L}(R^4)$.Le but de la deuxième partie est double : tout d'abord, on a décrit le défaut de compacité de l'injection de Sobolev de $H^1(R^2)$ dans les différentes classes d'espaces d'Orlicz, ensuite on a étudié une famille d'équations de Klein-Gordon non linéaires à croissance exponentielle. Cette étude inclut à la fois les problèmes d'existence globale, de complétude asymptotique et d'étude qualitative pour le problème de Cauchy associé. La troisième partie est dédiée à l'analyse des solutions de l'équation de Klein-Gordon 2D issues d'une suite de données de Cauchy bornée dans $H^1_{rad}(R^2)times L^2_{rad}(R^2)$. Basée sur les décompositions en profils, cette analyse a été conduite dans le cadre de la norme d'Orlicz / In this thesis, we focused on the one hand on the description of the lack of compactness of the critical Sobolev embedding into different classes of Orlicz spaces, and on the other hand on the study of the nonlinear Klein-Gordon equation with exponential nonlinearity. This work is divided into three parts. The aim of the first part is to characterize the lack of compactness of the Sobolev embedding of $H^2_{rad}(R^4)$ into the Orlicz space $mathcal{L}(R^4)$.The aim of the second part is twofold: firstly, we describe the lack of compactness of the Sobolev embedding of $H^1(R^2)$ into different classes of Orlicz spaces, secondly we investigate a family of nonlinear Klein-Gordon equations with exponential nonlinearity. This study includes both the global existence problem, the asymptotic completeness and the qualitative study for the associated Cauchy problem. The third part is dedicated to the analysis of the solutions to the 2D Klein-Gordon equation associated to a sequence of bounded Cauchy data in $H^1_{rad}(R^2)times L^2_{rad}(R^2)$. Based on the profile decompositions, this analysis was conducted in the framework of Orlicz norm
158

Ultrasound-Guided Percutaneous Thrombin Injection for Femoral Artery Pseudoaneurysms

McCoy, Dana W., Scharfstein, B, Walker, W., Evans, J. 01 October 2000 (has links)
We reviewed 13 cases of ultrasound-guided thrombin injection of femoral pseudoaneurysms. All cases occurred within a 17-month period from January 1998 through May 1999 and were complications of femoral artery puncture. Immediate total thrombosis occurred in nine of 13 patients. Twenty-four-hour follow-up ultrasound in seven patients revealed no recurrence of pseudoaneurysm. Two of 13 patients required operative repair. One pseudoaneurysm thrombosed with 15 minutes of compression after injection and one case required a second injection. No cases of arterial thrombosis were noted. Ultrasound-guided thrombin injection for femoral artery pseudoaneurysm represents a safe and effective alternative to operative repair.
159

Effectiveness of fluoroscopy-guided intra-articular steroid injection for hip osteoarthritis

Subedi, N., Chew, N.S., Chandramohan, M., Scally, Andy J., Groves, C. 05 September 2015 (has links)
No / To demonstrate the benefits of fluoroscopy-guided intra-articular steroid injection in the hip with varying degrees of disease severity, and to investigate the financial aspects of the procedure and impact on waiting time. MATERIALS AND METHODS: A prospective study was undertaken of patients who underwent fluoroscopic intra-articular steroid injection over the 9-month study period. Comparative analysis of the Oxford hip pain score pre- and 6-8 weeks post-intra-articular injection was performed. Hip radiographs of all patients were categorised as normal, mild, moderate, or severe disease (four categories) based on the modified Kellgren-Lawrence severity scale, and improvement on the Oxford hip pain score on each of these four severity categories were assessed. RESULTS: Within the study cohort of 100 patients, the mean increase in post-procedure hip score of 7.32 points confirms statistically significant benefits of the therapy (p<0.001, 95% confidence interval: 5.55-9.09). There was no significant difference in pre-injection hip score or change in score between the four severity categories (p=0.51). Significant improvement in hip score (p<0.05) was demonstrated in each of the four severity categories 6-8 weeks post-injection. No associated complications were observed. CONCLUSION: The present study confirms that fluoroscopy-guided intra-articular steroid injection is a highly effective therapeutic measure for hip osteoarthritis across all grades of disease severity with significant cost savings and the potential to reduce waiting times.
160

Évaluation du projet de prévention du passage à l'injection de drogue en Estrie : évaluation, innovation et concertation

Foley, Véronique 23 April 2018 (has links)
La prévalence de l’hépatite C est en constante évolution depuis les dix dernières années et constitue un enjeu de santé publique important. La prévalence est particulièrement élevée chez les utilisateurs de drogue par injection. La nécessité d’implanter des activités de prévention sur le passage à l’injection s’inscrit dans une perspective globale pour tenter d’enrayer le phénomène. Une formation portant sur la prévention du passage à l’injection de drogue chez les jeunes a été mise en place en Estrie, par l’Agence de santé et des services sociaux. Le présent mémoire s’est intéressé à l’évaluation d’implantation de ce projet en mettant en lumière les facteurs facilitants et les obstacles à la mise en œuvre des interventions de prévention sur le passage à l’injection, effectuées par les intervenants. Cela a également permis de recueillir des données régionales sur la clientèle desservie, les contextes d’interventions de même que les pistes de solution à envisager pour mieux orienter les actions de prévention et de formation. Le projet visait à ce que l’évaluation soit utile et utilisée par les décideurs régionaux et les intervenants sur le terrain. Les résultats ont démontré que la clientèle à risque est peu rejointe par les intervenants formés. Les intervenants agissent principalement auprès d’une clientèle qui utilise déjà des drogues par injection. Le manque de connaissances et d’aptitudes pour intervenir sur la prévention du passage à l’injection est parmi les obstacles principaux identifiés tout comme la réticence de certains milieux à l’aborder. La clientèle jeune et plus vulnérable est particulièrement difficile à rejoindre. Le travail sur le terrain et la concertation ont, entre autres, été nommés comme des facteurs facilitants. Plusieurs améliorations, visant à la fois la formation et les stratégies d’intervention, sont ainsi nécessaires pour permettre une amélioration de la mise en œuvre du projet.

Page generated in 0.1102 seconds